{"schema_version":"secwatch.filing_event.v1","accession":"0001689548-23-000157","form_type":"8-K","ticker":"PRAX","cik":"0001689548","company_name":"Praxis Precision Medicines, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.064782+00:00","generated_at":"2026-06-08T16:10:16.857114+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Praxis Q3 net loss $24.6M; starts Essential3 Phase 3 for ulixacaltamide","bullets":["Cash $101.1M as of Sep 30, 2023, providing runway into Q1 2025.","Initiated Essential3 Phase 3 program for ulixacaltamide in essential tremor; enrollment expected H1 2024.","Completed Part 1 dosing of EMBRAVE study for elsunersen in SCN2A-DEE; seeking FDA guidance.","R&D expenses $17.3M (down from $30.4M YoY); net loss $24.6M (down from $43.9M YoY).","Expects topline results from PRAX-628 Phase 2a PPR study in Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001689548-23-000157","json":"https://secwatch.observer/filing/0001689548-23-000157.json","markdown":"https://secwatch.observer/filing/0001689548-23-000157.md","text":"https://secwatch.observer/filing/0001689548-23-000157.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689548/000168954823000157/0001689548-23-000157-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689548/000168954823000157/prax-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T16:10:16.857114+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"532f868701b31a1ea5088a623f23b8c904ef5a15","claim":"Praxis Precision Medicines, Inc. reported the three months ended September 30, 2023 results: revenue $0.5 million, net income net loss of $24.6 million.","evidence_excerpt":"offerings of shares of Praxis’ common stock, partially offset by cash used in operations of $87.3 million during the nine months ended September 30, 2023. Praxis recognized $0.5 million in collaboration revenue during the three months ended September 30, 2023, related to its Option and License Agreement with UCB. Research and development expenses were $17.3","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954823000157/0001689548-23-000157-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2023"},{"label":"Revenue","value":"$0.5 million"},{"label":"Net income","value":"net loss of $24.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}